tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Dec 28;9(1):E13.
doi: 10.3390/vaccines9010013.
Comparison of Four SARS-CoV-2 Neutralization Assays
Lydia Riepler[SUP] 1 [/SUP], Annika R?ssler[SUP] 1 [/SUP], Albert Falch[SUP] 1 [/SUP], Andr? Volland[SUP] 1 [/SUP], Wegene Borena[SUP] 1 [/SUP], Dorothee von Laer[SUP] 1 [/SUP], Janine Kimpel[SUP] 1 [/SUP]
Affiliations
Abstract
Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID[SUB]50[/SUB]-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.
Keywords: SARS-CoV-2; neutralization assay; neutralizing antibodies; pseudotype virus.
. 2020 Dec 28;9(1):E13.
doi: 10.3390/vaccines9010013.
Comparison of Four SARS-CoV-2 Neutralization Assays
Lydia Riepler[SUP] 1 [/SUP], Annika R?ssler[SUP] 1 [/SUP], Albert Falch[SUP] 1 [/SUP], Andr? Volland[SUP] 1 [/SUP], Wegene Borena[SUP] 1 [/SUP], Dorothee von Laer[SUP] 1 [/SUP], Janine Kimpel[SUP] 1 [/SUP]
Affiliations
- PMID: 33379160
- DOI: 10.3390/vaccines9010013
Abstract
Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID[SUB]50[/SUB]-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.
Keywords: SARS-CoV-2; neutralization assay; neutralizing antibodies; pseudotype virus.